Proton NMR characterization of intact primary and metastatic melanoma cells in 2D & 3D cultures

Gokula Krishnan Ramachandran and Chen Hua Yeow

Abstract

Objective: To characterize the differences between the primary and metastatic melanoma cell lines grown in 2D cultures and 3D cultures.

Methods: Primary melanoma cells (WM115) and metastatic melanoma cells (WM266) extracted from a single donor was cultured in 2D as well as 3D cultures. These cells were characterized using proton NMR spectrometry, and the qualitative chemical shifts markers were identified and discussed.

Results: In monolayer culture (2D), we observed one qualitative chemical shift marker for primary melanoma cells. In spheroid cultures (3D), we observed nine significant chemical shifts, of which eight markers were specific for primary melanoma spheroids, whereas the other one marker was specific to metastatic melanoma spheroids. This study suggests that the glucose accumulation and phospholipid composition vary significantly between the primary and metastatic cells lines that are obtained from a single donor and also with the cell culturing methods. 14 qualitative chemical shift markers were obtained in the comparison between monolayer culture and spheroids cultures irrespective of the differences in the cell lines. Among which 4 were unique to monolayer cultures whereas 10 chemical shifts were unique to the spheroid cultures. This study also shows that the method of cell culture would drastically affect the phospholipid composition of the cells and also depicts that the cells in spheroid culture closely resembles the cells in vivo.

Conclusion: This study shows the high specificity of proton NMR spectrometry in characterizing cancer cell lines and also shows the variations in the glucose accumulation and phospholipid composition between the primary and metastatic melanoma cell lines from the same donor. Differences in the cell culture method does plays an important role in phospholipid composition of the cells.

Keywords: Nuclear magnetic resonance, Proton magnetic resonance spectrometry, Melanoma, Cancer
expression in metastatic melanoma when compared to primary melanoma [8]. These genes were found to be involved in cell adhesion, tumor suppression, cell cycle regulation and apoptosis. It is noteworthy that two proteins namely MAGEC1 (Melanoma antigen family c1) and FCRL1 (Fc receptor-like 1), which were known for melanoma progression were up-regulated in metastatic melanoma [8]. Another study showed that in primary melanoma SPRR1A/B, KRT16/17, CD24, LOR, GATA3, MUC15, and TMPRSS4 were up-regulated whereas, MAGE, GPR19, BCL2A1, MMP14, SOX5, BUB1, RGS20 were up-regulated in metastatic melanoma [9].

Coherent anti-Stokes Raman Scattering imaging revealed that free fatty acids (FFA) induced lipid accumulation in the cancer cells. FFA accumulation could adversely affect the cell–cell contact and promotes tissue invasion and positively correlated with the extend of metastasis [10]. Inhibition of the lipogenesis either by pharmacological drugs or using antisense shRNA resulted in the inhibition of tumor growth and metastasis after anti-angiogenic treatment [11, 12].

The higher levels of the choline related compounds were not only due to the biosynthetic pathways but also due to oncogene-induced activation of phosphatidyl choline and phosphatidyl ethanolamine-specific phospholipases. This resulted in the accumulation of choline related compounds in tumors or actively proliferating cells [13]. Differences in the concentration of choline-containing compounds could be considered as an indicator for accessing the clinical response of cancer to chemotherapy. The outcome of the chemotheraplay could be considered as positive if the choline-containing compounds decrease after the chemotheraplay [14]. It is reported that metastatic melanoma of lymph node can be detected using proton NMR spectroscopy with a sensitivity of 92.9% and specificity of 90.3% [15]. Chemical shifts of choline could alone separate the melanoma biopsies from non-melanoma biopsy with an accuracy of 69% [16]. Another study reported elevated levels of choline, taurine, lactate and amino acids like alanine, lysine, glutamine and glutamate in biopsies could be potential biomarkers for the identification of both primary and secondary melanoma cells [17]. From these studies, it is evident that proton NMR spectroscopy is capable enough in discriminating melanoma cells from non-melanoma cells.

The biomarkers identified by the MRI coupled with 1H-MRS and proton nuclear magnetic resonance spectrometry (1H-NMR) could be correlated, as both these methods evolve from the same principle where the former was the addition of imaging to the later [18]. In a recent study, proton nuclear magnetic resonance spectrometry identifies a unique chemical shift biomarker 1.28 ppm for the identification of the neural stem and progenitor cells (NPC). This method was used to identify the NPC in the live mouse using the same biomarker under proton magnetic resonance spectroscopy (1H-MRS) [19]. From the previous studies, it is clear that magnetic resonance can be employed for cancer diagnosis using the lipid signals, but the specificity of the magnetic resonance method in detecting cancerous tissues is still not well established.

We hypothesize that the proton NMR method has high specificity and capable of distinguishing biologically related cell lines. To test this hypothesis, we explore the specificity of proton NMR method by characterizing the primary and metastatic melanoma cells that were extracted from a single donor. The specimens we selected for this study were WM115 (primary melanoma) and WM266 (metastatic melanoma) cell lines. These cells are closely related as they are excised from the same donor and vary only in the stages of cancer. We also explored the differences in these cells grown as adherent cells and as multi-cellular tumor spheroids using proton NMR. If our hypothesis is correct, then it is evident that proton NMR shows high specificity and suitable for cellular level characterization.

**Methods**

**Cell culture**

WM-115 (human primary melanoma) and WM-266 (human metastatic melanoma) cells were purchased from American Type Culture Collection (ATCC), USA. These cells were cultured in eagle’s modified essential medium (EMEM) with 10% fetal bovine serum (FBS). For the comparison of different cell lines in vitro by nuclear magnetic resonance (NMR), it is necessary that the cells should have the same histologic origin and same growth medium [3]. All the experiments were carried out in triplicates for both the cell lines.

**Extraction of the intact cells**

The cells were cultured until they reached 90–95% confluence. The cells were washed twice with DPBS and harvested by trypsinization. The viability of the cells was checked by hemocytometer using bromophenol blue dye exclusion as a criterion for distinguishing live and dead cells. The samples with over 95% of viable cells were assumed to be suitable for the NMR spectrometry. The cells were diluted so that each sample has $1 \times 10^7$ cells.

**Formation of cellular spheroids**

For the spheroids formation, the cells were grown under 2D culture condition and harvested using trypsinization. The harvested cells were checked for viability as described above. These cells were diluted into $2.5 \times 10^6$ cells/mL and each sample is an aliquot of 4 mL containing...
$1 \times 10^7$ cells. The diluted cell samples were drawn into 20 μL droplets on the lid of the petri dish. The petri dish was filled with 10 mL of DPBS which forms the hydration chamber. The petri dish lid was gently inverted and placed in the incubator for the spheroid formation. The petri dish was then incubated for 3 days. After 3 days, the spheroids could be observed by the naked eye as white spheres. The spheroids were harvested and 600 μL of D$_2$O was poured gently on the harvested spheroids and carefully poured into the NMR tubes (Fig. 1).

**Nuclear magnetic resonance (NMR) spectrometry**

We performed one-dimensional $^1$H NMR spectrometry (DRX500, Bruker USA) on the collected samples and matched controls using deuterated water (D$_2$O) as the proton NMR solvent (Additional file 1: Figure S1). The acquired proton NMR spectral data was Fourier-transformed followed by phase and baseline correction using the Bruker XWinNMR software version 3.5. All the spectrums were aligned using the MNova 11 (Mestrelab Research, Spain) software. The visible peaks were manually picked and peak lists were extracted for the metabolite identification. The peak list was given as input to the Metaboanalyst 3.0 online statistical software (http://www.metaboanalyst.ca/, Canada) for statistical analysis [20].

**Results**

**NMR spectrum of the melanoma cells from monolayer culture and spheroid culture**

The peaks were binned together by the moving window of 0.03 ppm and a step of 0.015 ppm, which results in a group of 131 chemical shifts. The binned data was then normalized using generalized log transformation and auto scaling.

**Chemical shift markers identified using proton NMR analysis**

One-way ANOVA was performed for the identification of the statistically significant chemical shifts ($p < 0.05$). Among the significant chemical shifts ($p < 0.05$) markers, we focus only on the qualitative markers as they are more relevant for the clinical translation of this study. In the monolayer culture, the $^1$H NMR spectrums of the primary and metastatic melanoma cells were almost similar and varied only in their intensity (quantitative markers) expect the chemical shift at 5.86 ppm.

In the spheroid culture, we had observed several qualitative chemical shift markers for both primary and metastatic melanoma spheroids. Eight (3.58, 3.60, 3.67, 3.75, 4.12, 4.39, 6.16, 8.07 ppm) chemical shift markers were observed in the primary melanoma spheroids and one marker namely 8.25 ppm for metastatic melanoma spheroids (Fig. 2; Table 1).

Melanoma cells were observed to behave differently with different cell culture methods. In this analysis, we identified the chemical shifts that were unique to the cell line by excluding the chemical shifts that were specific to the cell culture method, irrespective of the cell lines. Comparison of primary melanoma cells cultured as monolayer and as spheroid yields five chemical shift markers (1.16, 2.71, 2.74, 3.04, 3.25 ppm) for primary melanoma cells cultured as monolayer and 10 chemical shift markers (2.19, 2.72, 2.93, 3.58, 3.61, 4.02, 4.12, 4.39, 6.07, 6.17 ppm) for primary melanoma cells cultured as spheroids (Fig. 3).
Similarly, in the case of metastatic melanoma cells, three chemical shift markers (3.08, 3.72–3.75, 3.90 ppm) were observed for metastatic melanoma cells cultured as monolayer and two (3.19 and 3.48 ppm) chemical shift markers were observed in metastatic melanoma cells cultured as spheroids (Fig. 4; Table 1).

In this study, we also intend to identify chemical shift markers with respect to the culturing method irrespective of the type of cell line. We were able to identify four chemical shift markers (2.85, 3.22, 3.96, 5.29 ppm) found only in the cells grown as monolayer and 10 chemical shift markers (2.72, 3.63, 3.66, 3.78, 4.05, 4.21, 4.32, 7.12, 7.44, 7.83 ppm) found specific to the cells grown as spheroids (Table 1).

Partial least square-discriminant analysis (PLS-DA) and clustering analysis performed between the primary and metastatic cells showed that culturing method had a more dominant influence over their $^1$H NMR spectrum than the cell line differences (Fig. 5).

**Discussions**

**Guanosine as the biomarker for primary melanoma in monolayer culture**

This chemical shift 5.86, which was unique to the primary melanoma cells cultured as monolayer is assigned to guanosine, which is the integral part of the cGMP, an important second messenger in various intra-cellular signal transduction pathways. This suggests that under monolayer culture, guanosine is the biomarker of primary melanoma cells (WM115).

**Primary melanoma spheroids and metastatic spheroids vary in glucose accumulation and phospholipid composition**

The identified chemical shift markers of primary melanoma spheroids were assigned to threonine (3.58, 3.60 ppm), glucose (3.67, 6.16 ppm), glycerol phosphoethanolamine (4.12 ppm) $N$-acetyl-galactosaminitol (4.39 ppm) and NH$_2$ proton (8.07 ppm) (Table 1). The chemical shift marker of the metastatic melanoma spheroids was assigned to ATP (8.25 ppm). The primary melanoma spheroids suggest the presence of amino acid threonine which could indicate the presence of a membrane protein that was rich in threonine. Threonine had been reported in the literature as a biomarker for ER (endocrine hormone receptor) positive breast cancer [23]. Interestingly primary melanoma spheroids had been found to have glucose, a key energy source that was not detected in metastatic melanoma spheroids. It had been shown that during the detachment of cells from the...
Table 1  List of qualitative chemical shift markers and its chemical shift assignment

| S. no | Cell line/culture type | ¹H NMR markers (ppm) | Assignment | Reference |
|-------|-------------------------|----------------------|------------|-----------|
| 1     | 2D Primary melanoma     | 5.86 (d)             | Guanosine  | [21]      |
| 2     | Metastatic melanoma     | –                    | –          | –         |
| 3     | 3D Primary melanoma     | 3.58 (d)             | Threonine  | [22, 23]  |
|       |                         | 3.60 (d)             | Threonine  | [24]      |
|       |                         | 3.67 (s)             | Glucose    | [23]      |
|       |                         | 3.75                 | Glutamine  |           |
|       |                         | 4.12 (t)             | Glycerophosphoethanolamine | [25, 26] |
|       |                         | 4.39 (s)             | N-Acetylgalactosaminol | [27]     |
|       |                         | 6.16 (d)             | Glucose    | [28]      |
|       |                         | 8.07 (s)             | NH₂        | [29]      |
| 4     | Metastatic melanoma     | 8.25 (s)             | ATP        | [30]      |
| 5     | Primary melanoma 2D     | 1.16 (s)             | Lipids     | [31]      |
|       |                         | 2.71 (s)             | Dimethylamine | [32]   |
|       |                         | 2.74 (s)             | Dimethylamine | [33]   |
|       |                         | 3.04                 | Creatine/phosphocreatine | [25] |
|       |                         | 3.25 (s)             | Choline head groups of phospholipids | [36] |
|       |                         | 2.19 (s)             | Adipate    | [37]      |
|       |                         | 2.72 (t)             | Unassigned |           |
|       |                         | 2.93 (s)             | Dimethyl glycine | [26] |
|       |                         | 3.58 (d)             | Threonine  | [23]      |
|       |                         | 3.61 (d)             | Glycerol   | [38]      |
|       |                         | 4.02 (s)             | 2 Hydroxyglutarate | [39, 40] |
|       |                         | 4.12 (t)             | Glycerophosphoethanolamine | [38] |
|       |                         | 4.39 (s)             | N-Acetylgalactosaminol | [27]     |
|       |                         | 6.07 (d)             | Unassigned |           |
|       |                         | 6.17 (s)             | Unassigned |           |
| 6     | 3D Metastatic melanoma  | 3.08                 | Methyl lysine | [40] |
|       |                         | 3.72–3.75 (q)        | Unassigned |           |
|       |                         | 3.90 (s)             | Glucose    | [42]      |
| 7     | Metastatic melanoma 2D  | 3.19 (s)             | O-Acetylcarnitine | [37] |
|       |                         | 3.48 (s)             | Unassigned |           |
| 8     | 3D                      | 3.85 (s)             | Asparagine | [43]      |
|       |                         | 3.22                 | Choline    | [25]      |
|       |                         | 3.96 (t)             | β-β-Cyclodextrin | [44] |
|       |                         | 5.29 (s)             | Hc–ch (l, ch) | [31] |
| 9     | 2D                      | 2.72 (t)             | Unassigned |           |
|       |                         | 3.63 (s)             | Glycerol   | [38]      |
|       |                         | 3.66                 | Glycerol/inositol | [38] |
|       |                         | 3.78                 | Phosphoinositol | [45] |
|       |                         | 4.05 (t)             | Ethanolamine | [45] |
|       |                         | 4.21                 | Phosphocholine | [38] |
|       |                         | 4.32                 | Glycerophosphocholine | [31] |
|       |                         | 7.12 (s)             | Ar–H       | [31]      |
|       |                         | 7.44 (d)             | Unassigned |           |
|       |                         | 7.83 (s)             | Amide (–NH) | [37]      |
Fig. 3 1D $^1$H NMR spectra showing the qualitative chemical shift markers between WM115 monolayer and WM115 spheroids

Fig. 4 1D $^1$H NMR spectra showing the qualitative chemical shift markers between WM266 monolayer and WM266 spheroids
extracellular matrix, the cancer cells stopped the glucose consumption that resulted in energetic stress. In melanoma, it was shown that during metastasis the ROS levels increase dramatically, which could be attributed to the cessation in the glucose uptake. When the glucose consumption was stopped the ATP production would cease, but we observed ATP as the biomarker for metastatic melanoma, this is because once the ATP level starts to decline AMP-activated protein kinase (AMPK) will be activated and inhibit fatty acid synthesis and activate fatty acid oxidation pathway. This shift in the fatty acid metabolism resulted in the generation of NADPH and promotes the generation of α-ketoglutaric acid from isocitric acid, which also increased the NADPH. This NADPH which is generated by the AMPK activation could enter into the electron transport chain resulting in the synthesis of ATP [46]. N-Acetylgalactosaminol, observed in the primary melanoma spheroids, forms an integral part of cancer associated glycoproteins [50].

Differences in the cell culturing method are primarily reflected in the phospholipid composition

The comparison of the chemical shifts of the cells cultured as monolayers and cells cultured as spheroids irrespective of the cell line differences we could observe chemical shift signatures for both monolayer cultures as well as the spheroid cultures. The chemical shift signatures of the monolayer cultures were assigned to Asparagine (2.85 ppm), choline compounds (3.22 ppm), β-cyclodextrin (3.96 ppm), and lipids (5.29 ppm). From our data, the presence of lipids and choline compounds, which formed the plasma membrane were evident in the monolayer cultures as more cellular surface area had been exposed compared to the cells in the spheroid culture. The triplet at 3.96 is assigned to β-cyclodextrin, but the biological origin of this compound is unclear. They have a very interesting property of forming inclusion complexes with various lipophilic compounds [44].

On the other hand the chemical shift signatures of the spheroids were assigned to glycerol (3.63 and 3.66 ppm), inositol (3.66 ppm), phosphoinositol (3.78 ppm), ethanolamine (4.05 ppm), phosphocholine (4.21 ppm), glycerophosphocholine (4.32 ppm) and amide group (–NH) (7.83 ppm). The presence of glycerol, inositol, ethanolamine, phosphocholine and glycerophosphocholine shows the existence of the glycerophospholipids, the key component of cell membrane suggests that the multicellular spheroids closely resembles the cells in vivo.
Differences in the culturing method is reflected in the phospholipid of primary melanoma cells

Primary melanoma cells showed differences in their behavior with respect to the culturing method. The markers of primary melanoma cultured as monolayer were assigned to lipids (1.16, 5.29 ppm), dimethylamine (2.71, 2.74 ppm), phosphocreatine (3.04 ppm) and choline head groups of phospholipids (3.25 ppm). Thus primary melanoma cells in monolayer produce certain common cell membrane components like choline and lipids. They also contain phosphocreatine a key reserve for the high energy phosphates, which could be utilized for the formation of ATP. Dimethylamine could be the result of L-citrulline formation from asymmetric dimethyl arginine (ADMA) [48]. On the other-hand when these same primary melanoma cells were cultured as spheroids they produce some unique chemical shift signatures that could be assigned to adipate (2.19 ppm), dimethyl glycine (2.93 ppm), threonine (3.58 ppm), glycerol (3.61 ppm), 2-hydroxy glutarate (4.02 ppm), glycerophosphoethanolamine (4.12 ppm), N-acetylgalactosaminol (4.39 ppm). Adipate is an acidity regulator, which plays a vital role in maintaining the acidity balance in the cellular microenvironment. This acidity regulation is very important as the cells would produce lactate as a result of their metabolic activity. Glycerol and glycerophosphoethanolamine were the integral components of the phospholipids in the cell membrane. This suggests that the 3D architecture of the multicellular spheroids of the metastatic melanoma cells vary from their monolayer counterpart primarily in the plasma membrane composition. 2-Hydroxy glutarate (2-HG) is a well known as oncometabolite which will usually accumulate in malignant cells due to the gain of function mutation of the isocitric dehydrogenases (IDH). Accumulation of the 2-HG inhibits the 2-oxo glutarate dependent oxygenases which in turn inhibits histone lysine demethylases thus impairing the epigenetic modifications of histones [49, 50]. This proves the closeness of the 3D spheroids with the in vivo tissues. Previous studies on the rectal adenocarcinoma had shown that N-acetylgalactosaminol forms an integral part in all the four oligosaccharides isolated from the mucin-like glycoprotein of rectal adenocarcinoma. Clearly, N-acetylgalactosaminol involves in the formation of cancer associated glycoproteins [47].

Glucose accumulation and O-acetyl carnitine mark the differences between the metastatic melanoma cells cultured as monolayer and as spheroids

Variations in the chemical shift signatures with respect to the culturing method was also observed in the metastatic melanoma cells. The chemicals shifts of the monolayer cultured cells suggested the presence of methyl lysine (3.08 ppm), glucose (3.90 ppm), and whereas the chemical shifts of metastatic melanoma spheroids revealed the presence of O-acetyl carnitine (3.19 ppm). This data showed that methyl lysine and glucose resonating at 3.08 and 3.90 ppm respectively were the qualitative markers for the metastatic melanoma cells cultured as monolayer but the same cell line when cultured as spheroids they don’t produce chemical shift peaks at 3.08 and 3.90 ppm instead they produce a chemical shift at 3.19 which is assigned to O-acetyl carnitine. The chemical shift at 3.08 is attributed to proton from the CH₂ group of the methyl lysine. Although it is previously reported that, this chemical shift manifested the presence of the SH₂ group in taurine [51, 52]. In these studies, the 3.08 ppm chemical shift has appeared as a triplet, but in our data, the 3.08 ppm appear as a singlet. In a previous report, where the chromatin core particles where analyzed using proton nuclear magnetic resonance spectrometry encountered the 3.08 ppm chemical shift as a singlet, and it was assigned to the CH₂ group proton of the methyl lysine [41]. Methylated amino acids especially methyl-lysine and methyl-arginine in the chromatin plays a vital role in recruiting proteins that induce structural changes in chromatin thus influencing gene expression and repression [53].

Clinical projections of this study

In this study, we used the 3D spheroids, in order to minimize the limitations in its clinical translation. Flat monolayer cultures were the simplistic cancer models, having a physiologically uniform environment and lacked in the cell to cell attachment, which is not the case in the actual tumor environment. In in vivo tumors there exists cell to cell attachment, oxygen gradient, nutrition gradient and waste gradient. This behavior can be reproduced by culturing cells as 3D spheroids [54]. 2D flat monolayer cultured cells showed apical–basal polarity and lacks histological differentiation of the in vivo tumors, whereas histological morphology similar to the in vivo tumor can be achieved in 3D spheroids. [55, 56]. Like the in vivo tumors, 3D spheroids exhibit phenotypic heterogeneity in the cell proliferation rate, gene expression and differentiation which led to the heterogeneity in the function and morphology [57]. Few cells exhibited the stem cell-like characteristics such as self-renewal and undifferentiated multipotent phenotype called cancer stem cells (CSCs) [58]. These CSCs were observed in both in vitro 3D tumor spheroids and in vivo tumors [59], and these stemness related genes were found to be upregulated in 3D spheroids compared to the 2D monolayers [60]. All the above studies showed the cells grown as 3D spheroids
resemble closely to the cells in the in vivo tumors. Thus, we expect there won’t be any potential limitations in the clinical translation of the results of this study and of course an actual clinical translational study is necessary to corroborate this statement.

Conclusion
In this study, we showed that the two closely associated cell lines, which were obtained from the same donor and differed only in the stages of melanoma could be identified as different cell lines by employing 1D 1H NMR spectrometry. Thus proving the specificity of this method in characterizing cancer cell lines. Our study suggests that the glucose accumulation and phospholipid composition vary significantly between the primary and metastatic cell lines that were obtained from a single donor and also with the cell culturing methods. These results encourage further researches on understanding the effects of phospholipid and glucose accumulation in cancer development, progression and invasion. This study also showed that the method of cell culture would drastically affect the phospholipid composition of the cells and also depicts that the cells in spheroid culture closely resembled the cells in vivo.

Additional file

Additional file 1: Figure S1. (A) 1D H1 NMR spectrum of media control for primary melanoma cells. (B) 1D H1 NMR spectrum of media control for metastatic melanoma cells. (C) 1D H1 NMR spectrum of spent media control for metastatic melanoma spheroids (WM115). (D) 1D H1 NMR spectrum of spent media control for metastatic melanoma spheroids (WM266). (E) 1D H1 NMR spectrum of trypsin. (F) 1D H1 NMR spectrum of DPBS.

Abbreviations
NMR: nuclear magnetic resonance; 1D: one dimensional; 1H: proton; ATCC: American Type Culture Collection; FBS: fetal bovine serum; EMEM: Eagle’s minimum essential medium; MAGE: melanoma antigen family; BCL2A1: B-cell lymphoma 2-related protein A1; BUB: budding uninhibited by benzimidazoles; RGS: regulators of G-protein signaling; MUC: mucins; GATA: globin transcription factor.

Authors’ contributions
RGK conceived the study, designed the experiments, carried out the experiments, did data analysis and prepared the manuscript. YCH helped in designing experiments and preparing the manuscript. Both authors read and approved the final manuscript.

Acknowledgements
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Funding
This research is supported by the MOE Academic research fund (AcRF) Tier-1 Grant (R397-000-143-133).

Received: 5 August 2016   Accepted: 2 March 2017
Published online: 16 March 2017

References
1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No.11 [Internet]. Lyon, France: International Agency for Research on Cancer, 2013. Available from: http://globocan.iarc.fr
2. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed. 1992;5:303–24.
3. Ruiz-caballero J, Cohen JS. Phospholipid metabolites as indicators of cancer cell function. NMR Biomed. 1992;5:226–33.
4. Bolan PJ, Meisamy S, Baker EH, Lin J, Emory T, Nelson M, Everson LL, Yee D, Garwood M. In vivo quantification of cholesterol compounds in the breast with 1H NMR spectroscopy. Magn Reson Med. 2003;50:1–10.
5. Bolan PJ, Nelson MT, Yee D, Garwood M. Imaging in breast cancer: magnetic resonance spectroscopy. Breast Cancer Res. 2005;7:149–52.
6. Jacobs MA, Barker PB, Bottomley PA, Bhujwalla Z, Blumeke DA. Proton magnetic resonance spectroscopic imaging of human breast cancer: a preliminary study. J Magn Reson Imaging. 2004;19:688–75.
7. Gillies RJ, Morse DL. In vivo magnetic resonance spectroscopy in cancer. Annu Rev Biomed Eng. 2005;7:287–326.
8. Koh SS, Wei J-P, Li X, Huang RR, Doan NB, Scolyer R, Binder SW, et al. Differential gene expression profiling of primary cutaneous melanoma and sentinel lymph node metastases. Mod Pathol. 2012;25(6):828–37.
9. Riker AI, Enker K, Roos SL, Liu S, Ren S, Morris C, Matta J, et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genom. 2008;1:13.
10. Le TT, Huff TB, Cheng J-X. Coherent anti-Stokes Raman scattering imaging of lipids in cancer metastasis. BMC Cancer. 2009;9:42.
11. Sounni NE, Cimino J, Blacher S, Primac I, Truong A, Mazzucchelli G, Noel A, et al. Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal. Cell Metab. 2014;20(2):280–94.
12. Sparling ML. Analysis of mixed lipid extracts using 1H NMR spectra. Comput App Biosci. 1990;6(1):29–42.
13. Podo F. Tumor phospholipid metabolism. NMR Biomed. 1999;12:413–39.
14. Bolan PJ, Baker EH, Bliss RL, Gulbahce E, Everson LI, Nelson MT, Emory TH, Tuttle TM, Yee D, Garwood M. Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo 1H MR spectroscopy—a pilot study at 4 T. Radiology. 2004;234:242–31.
15. Stretch JR, Somorjai R, Bourne R, Hisao E, Scolyer RA, Dolenko B, Thompson JF, Mountford CE, Lean CL. Melanoma metastases in regional lymph nodes are accurately detected by proton magnetic resonance spectroscopy of fine-needle aspirate biopsy samples. Ann Surg Oncol. 2005;12(11):943–9.
16. Guttner P, Bourgeat P, Stretch JR, Scolyer RA, Ourselin S, Lean C, Thompson JF, Bourne R. Diagnostic value of 8.5 T magnetic resonance spectroscopy of benign and malignant skin lesion biopsies. Melanoma Res. 2010;20(4):311–7.
17. Bourne RM, Stanwell P, Stretch J, Scolyer RA, Thompson JF, Mountford CE, Lean CL. In vivo and ex vivo proton MR spectroscopy of primary and secondary melanoma. Eur J Radiol. 2005;53(3):506–13.
18. Pohost GH, Elgavish GA, Evanochko WT. Nuclear magnetic resonance: with or without nuclear? J Am Coll Cardiol. 1986;7:709–10.
19. Manganas LN, Zhang X, Li Y, Hazel RD, Smith SD, Waghshle ME, Henn F, Benveniste F, Djuric PM, Enikolopov G, Maletic-Savatic M. Magnetic resonance spectroscopy identifies neural progenitor cells in the live human brain. Science. 2007;318:980–5.
20. Xia J, Wishart DS. Web-based inference of biological patterns, functions and pathways from metabolomic data using MetaboAnalyst. Nat Protoc. 2011;6:743–60.
21. Guerlera A, Kumar Bajpai N, Rawat A, Khetrapal CL, Prasad N, Kumar D. Metabolite characterization in pentonental daisys effluent using high-resolution 1H and 13C NMR Spectrosc. Magn Reson Chem. 2014;52(9):475–9.

22. Allen JR, Post RW, Griffth OW, Erickson SJ, Erickson B. In vivo proton (1H) magnetic resonance spectroscopy for cervical carcinoma. Am J Clin Oncol. 2001;24(5):522–9.

23. Lean C, Doran S, Somorjai RL, Malycha P, Clarke D, Himmelreich U, Bourne R, Dolbenko D, Nikulin AE, Mountford C. Determination of grade and receptor status from the primary breast lesion by magnetic resonance spectroscopy. Technol Cancer Res Treat. 2004;3(6):551–6.

24. Behar KL, Oginato T. Assignment of resonance in the 1H spectrum of rat brain by two-dimensional shift correlated and J-resolved NMR spectroscopy. Magn Reson Med. 1991;17(2):285–303.

25. Cheng LL, Lean CL, Bogdanova A, Wright SC, Ackerman JL, Brady TJ, Garrido L. Enhanced resolution of proton NMR spectra of malignant lymph nodes using magic-angle spinning. Magn Reson Med. 1996;36(5):653–8.

26. Martinez-Granados B, Monleon D, Martinez-Bisbal MC, Rodrigo JM, del Olmo J, Liuch P, Fernandez A, Mari-Bonmati L, Celda B. Metabolite identification in human liver needle biopsies by high-resolution magic angle spinning. 1H NMR spectroscopy. NMR Biomed. 2006;19(1):90–100.

27. Mutsaers JH, van Halbeek H, Vliegenthart JF, Wu AM, Kabat E. Typing of core and backbone domains of mucin-type oligosaccharides from a human ovarian-cyst glycoproteins by 500-MHz 1H-NMR spectroscopy. Eur J Biochem. 1986;157(1):139–46.

28. Feng J, Isem N, Burton S, Hu J. Studies of secondary melanoma on C57BL/6 J mouse using 1H NMR metabolomics. Metabolites. 2013;3(4):1011–35.

29. Soliman FMA, Dawoud NTA, Hamza RM. Synthesis, biological and anti-tumor evaluation of some new nucleosides incorporating heterocyclic moieties. Am J Org Chem. 2015;5(5):137–48.

30. Abramov Y, Camisi M, Anteby SO, Ringel I. Ex vivo 1H and 31P magnetic resonance spectroscopy as a means for tumor characterization in ovarian cancer patients. Oncol Rep. 2013;29(1):321–8.

31. Gottschalk M, Ivanova G, Collins DM, Eustace A, O’Connor R, Brougham DF. Metabolic studies of human lung carcinoma cell lines using in vitro 1H NMR of whole cells and cellular extracts. NMR Biomed. 2008;21:448–67.

32. Assagio VM, Nagana Gowda GA, Zhang S, Shanaha N, Clark J, Raffety D. Use of EDTA to minimize ionic strength dependent frequency shifts in the 1H NMR spectra of urine. Metabolomics. 2008;4(4):328–36.

33. Cox JJ, Aliev AE, Crossley MME, Dawood M, Al-Mahtab M, Akbar SM, Rahman S, Riva A, Williams R, Taylor-Robinson DS. Urinary nuclear magnetic resonance spectroscopy of a Bangladeshi cohort with hepatitis-B hepato-cellular carcinoma: a biomarker corroboration study. World J Gastroenterol. 2016;22(16):4191–200.

34. Bell JD, Sadler PJ, Macleod AF, Turner PR, La Ville A. 1H NMR studies of human blood plasma. Assignment of resonances for lipoproteins. FEBS Lett. 1987;219(1):239–43.

35. Wang H, Wang L, Zhang H, Deng P, Chen J, Zhou B, Hu J, Zou J, Lu W, Xiang P, Wu T, Zhao Y-L. ¹H NMR-based metabolic profiling of human 1H NMR metabonomic characterization in peritoneal dialysis effluent using high-resolution proton magnetic resonance spectroscopy cell type-specific fingerprinting of meningioma and meningeal cells by proton magnetic resonance spectroscopy. Cancer Res. 1995;55:420–7.

36. Li, Xu S, Woon EC, McDonough MA, Kawamura A. The oncometabolite 2-hydroxylutarate inhibits histone lysine demethylases. EMBO Rep. 2011;12(5):463–9.

37. Chowdhury R, Yeoh KK, Tian Y, Hillringhaus L, Bagg EA, Rose NR, Leung IK, Ku S, Woon EC, McDonough MA, Kawamura A. The oncometabolite 2-hydroxylutarate inhibits histone lysine demethylases. EMBO Rep. 2011;12(5):463–9.

38. Sorensen AG, Rosen BR. Review series Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. Magn Reson Med. 2008;60(1):33–40.

39. Baker BM, Chen CS. Deconstructing the third dimension: how 3D culture microenvironments alter cues. J Cell Sci. 2012;125(Pt 13):3015–24.

40. Lee J, Myungjin, Mhawwech-Fauceglia P, Lee N, Parsian LG, Gayther SA, Lawrence K. A three dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro. Lab Invest. 2013;93(5):528–40.

41. Cary PD, Moss T, Bradbury EM. High-resolution proton-magnetic resonance studies of chromatin core particles. Eur J Biochem/FEBS. 1978;89(2):475–82.

42. Tate AR, Foxall PJ, Holmes E, Moka D, Spraul M, Nicholson JK, Landon JC. Distinction between normal and renal cell carcinoma kidney cortical biopsy samples using pattern recognition of 1H magic angle spinning (MAS) NMR spectra. NMR Biomed. 2000;13(2):64–71.

43. Schenetti L, Mucci A, Parenti F, Cagnoli R, Righi V, Tosi MR, Tugnoli V. HR-MAS NMR spectroscopy in the characterization of human tissues: application to healthy gastric mucosa. Concepts Magn Reson Part A. 2006;28A(3):430–43.

44. Guo Q-X, Li Z, Ren TAN, Zhu X, Liu Y. Inclusion complexation of sodium alky sulfates with β-cyclodextrin. A ¹H NMR study, journal of inclusion phenomena and molecular recognition. Chemistry. 1994;1994(7):149–56.

45. Knat M, Vion-Dury J, Confort-Gouny S, Favre R, Vout P, Scialy M, Sari H, Conzeo P. Analysis of plasma lipids by NMR spectroscopy: application to modifications induced by malignant tumors. J Lipid Res. 1993;34:1009–19.

46. Hay N. Programming glucose metabolism in cancer: can it be exploited for cancer therapy? Nat Rev Cancer. 2016;16(10):635–49.

47. Kurosaka A, Nakajima H, Funakoshi I, Matsuyma M, Nagayo T, Yamashina I. Structures of the major oligosaccharides from a human rectal adenocarcinoma glycoprotein. J Biol Chem. 1983;258(19):11594–8.

48. Tsikas D, Thum T, Becker T, Pham VV, Chobanyan K, Mitschke A, Beckmann B, Gutzki FM, Bauersachs J, Stichtenoth DO. Accurate quantification of dimethylamine (DMA) in human urine by gas chromatography–mass spectrometry as pentfluorobenzenamide derivative: Evaluation of the relationship between DMA and its precursor asymmetric dimethylarginine (ADMA) in health and disease. J Chomatogr B Anal Technol Biomed Life Sci. 2007;851(1–2):229–39.

49. Chowdhury R, Yeoh KK, Tian Y, Hillringhaus L, Bagg EA, Rose NR, Leung IK, Ku S, Woon EC, McDonough MA, Kawamura A. The oncometabolite 2-hydroxylutarate inhibits histone lysine demethylases. EMBO Rep. 2011;12(5):463–9.

50. Dang L, White DW, Gross S, Bennett BD, Bittinger EM, Driggers EM, Fantin VR, Jiang HG, Jin S, Keenan MC, Marks KM, Su SM. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739–44.

51. Florian CL, Preece NE, Bhakoo KK, Williams SR, Noble MD. Cell-type specific fingerprinting of meningioma and meningeval cells by proton nuclear magnetic resonance spectroscopy cell type-specific fingerprinting of meningioma and meningeval cells by proton nuclear magnetic resonance spectroscopy. Cancer Res. 1995;55:420–7.

52. Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci. 1993;13(3):981–9.

53. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov. 2012;11(5):384–400.

54. Lin RZ, Chang HY. Recent advances in three-dimensional multielement spheroid culture for biomedical research. Biotechnol J. 2008;3(9–10):139–51.

55. Baker BM, Chen CS. Deconstructing the third dimension: how 3D culture microenvironments alter cues. J Cell Sci. 2012;125(Pt 13):3015–24.

56. Lee J, Myungjin, Mhawwech-Fauceglia P, Lee N, Parsian LG, Gayther SA, Lawrence K. A three dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro. Lab Invest. 2013;93(5):528–42.

57. Marjanovic ND, Weinberg RA, Chaffer CL. Cell plasticity and heterogeneity exploited for cancer therapy? Nat Rev Cancer. 2016;16(10):635–49.